Clinical pharmacology in drug developmentHumansTherapeutic EquivalencyInjectionsSubcutaneousMale
A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single-Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers.
Angela Jeong, Kathleen Weisel, Dessislava Dimitrova, Brianna Donnelly, Daniel Wang, An Vermeulen, Zhenhua Xu
Published: 202610.1002/cpdd.70007
Abstract
Guselkumab is approved for the treatment of psoriasis, psoriatic arthritis, as well as ulcerative colitis and Crohn's disease. Two delivery devices for subcutaneous (SC) injection previously had been approved for the administration of 100 mg guselkum…
Preview only. Read the full abstract at the source